Abstract
Background: Suppression of hepatitis B virus (HBV) DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV-related decompensated cirrhosis patients is unclear. Aims: To compare virologic response, changes in liver function, clinical course and predictive factors for early mortality after treatment between patients treated with lamivudine and those with entecavir in HBV-related decompensated cirrhosis patients. Methods: HBV-related decompensated cirrhosis patients [Child-Turcotte-Pugh (CTP) score ≥ 7] treated with either lamivudine or entecavir were enrolled. Serum HBV DNA levels, CTP score and Model for End-stage Liver Disease (MELD) score were monitored every 3 months. Results: Eighty-six patients were enrolled; mean age was 54 ± 11 years, and 63 (73.3%) patients were men; 41 (47.7%) and 45 (52.3%) patients were assigned to the lamivudine group and entecavir group respectively. Although suppression of serum HBV DNA level was more potent in the entecavir group, CTP or MELD scores during the course of treatment did not differ between the two groups. Similarly, 6-month survival rates did not differ between the two groups (95.1 vs 93.2%, P = 0.684). Baseline CTP score and MELD score at 3 months of treatment were significantly associated with 6-month mortality. The 6- and 12-month mortality rates for patients with baseline CTP score ≥11 and MELD score ≥17.5 after 3 months of treatment were 42.9 and 61.9% respectively. Conclusions: Although HBV DNA suppression was more potent in the entecavir group than the lamivudine group, early mortality rates did not differ between the two groups. The baseline CTP score and MELD score 3 months after initiating antiviral treatment were significant predictors of early mortality.
| Original language | English |
|---|---|
| Pages (from-to) | 656-664 |
| Number of pages | 9 |
| Journal | Liver International |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2012 Apr 1 |
Fingerprint
Keywords
- Cirrhosis
- Decompensation
- Entecavir
- Hepatitis B virus
- Lamivudine
ASJC Scopus subject areas
- Hepatology
Cite this
Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. / Hyun, Jong Jin; Seo, Yeon Seok; Yoon, Eileen; Kim, Tae Hyung; Kim, Dong Jin; Kang, Hyun Seok; Jung, Eun Suk; Kim, Jeong Han; An, Hyonggin; Kim, Ji Hoon; Yim, Hyung Joon; Yeon, Jong Eun; Lee, Hong Sik; Byun, Kwan Soo; Um, Soon-Ho; Kim, Chang Duck; Ryu, Ho Sang.
In: Liver International, Vol. 32, No. 4, 01.04.2012, p. 656-664.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis
AU - Hyun, Jong Jin
AU - Seo, Yeon Seok
AU - Yoon, Eileen
AU - Kim, Tae Hyung
AU - Kim, Dong Jin
AU - Kang, Hyun Seok
AU - Jung, Eun Suk
AU - Kim, Jeong Han
AU - An, Hyonggin
AU - Kim, Ji Hoon
AU - Yim, Hyung Joon
AU - Yeon, Jong Eun
AU - Lee, Hong Sik
AU - Byun, Kwan Soo
AU - Um, Soon-Ho
AU - Kim, Chang Duck
AU - Ryu, Ho Sang
PY - 2012/4/1
Y1 - 2012/4/1
N2 - Background: Suppression of hepatitis B virus (HBV) DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV-related decompensated cirrhosis patients is unclear. Aims: To compare virologic response, changes in liver function, clinical course and predictive factors for early mortality after treatment between patients treated with lamivudine and those with entecavir in HBV-related decompensated cirrhosis patients. Methods: HBV-related decompensated cirrhosis patients [Child-Turcotte-Pugh (CTP) score ≥ 7] treated with either lamivudine or entecavir were enrolled. Serum HBV DNA levels, CTP score and Model for End-stage Liver Disease (MELD) score were monitored every 3 months. Results: Eighty-six patients were enrolled; mean age was 54 ± 11 years, and 63 (73.3%) patients were men; 41 (47.7%) and 45 (52.3%) patients were assigned to the lamivudine group and entecavir group respectively. Although suppression of serum HBV DNA level was more potent in the entecavir group, CTP or MELD scores during the course of treatment did not differ between the two groups. Similarly, 6-month survival rates did not differ between the two groups (95.1 vs 93.2%, P = 0.684). Baseline CTP score and MELD score at 3 months of treatment were significantly associated with 6-month mortality. The 6- and 12-month mortality rates for patients with baseline CTP score ≥11 and MELD score ≥17.5 after 3 months of treatment were 42.9 and 61.9% respectively. Conclusions: Although HBV DNA suppression was more potent in the entecavir group than the lamivudine group, early mortality rates did not differ between the two groups. The baseline CTP score and MELD score 3 months after initiating antiviral treatment were significant predictors of early mortality.
AB - Background: Suppression of hepatitis B virus (HBV) DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV-related decompensated cirrhosis patients is unclear. Aims: To compare virologic response, changes in liver function, clinical course and predictive factors for early mortality after treatment between patients treated with lamivudine and those with entecavir in HBV-related decompensated cirrhosis patients. Methods: HBV-related decompensated cirrhosis patients [Child-Turcotte-Pugh (CTP) score ≥ 7] treated with either lamivudine or entecavir were enrolled. Serum HBV DNA levels, CTP score and Model for End-stage Liver Disease (MELD) score were monitored every 3 months. Results: Eighty-six patients were enrolled; mean age was 54 ± 11 years, and 63 (73.3%) patients were men; 41 (47.7%) and 45 (52.3%) patients were assigned to the lamivudine group and entecavir group respectively. Although suppression of serum HBV DNA level was more potent in the entecavir group, CTP or MELD scores during the course of treatment did not differ between the two groups. Similarly, 6-month survival rates did not differ between the two groups (95.1 vs 93.2%, P = 0.684). Baseline CTP score and MELD score at 3 months of treatment were significantly associated with 6-month mortality. The 6- and 12-month mortality rates for patients with baseline CTP score ≥11 and MELD score ≥17.5 after 3 months of treatment were 42.9 and 61.9% respectively. Conclusions: Although HBV DNA suppression was more potent in the entecavir group than the lamivudine group, early mortality rates did not differ between the two groups. The baseline CTP score and MELD score 3 months after initiating antiviral treatment were significant predictors of early mortality.
KW - Cirrhosis
KW - Decompensation
KW - Entecavir
KW - Hepatitis B virus
KW - Lamivudine
UR - http://www.scopus.com/inward/record.url?scp=84858295076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858295076&partnerID=8YFLogxK
U2 - 10.1111/j.1478-3231.2011.02676.x
DO - 10.1111/j.1478-3231.2011.02676.x
M3 - Article
VL - 32
SP - 656
EP - 664
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 4
ER -